Emergent BioSolutions (EBS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for April 29, 2026, at 9 a.m. Eastern Time.
Eligible shareholders as of March 6, 2026, are encouraged to participate and vote.
Voting matters and shareholder proposals
Shareholders can vote by proxy if unable to attend the virtual meeting.
Voting instructions provided via email from E*TRADE, with support available for account access issues.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Emergent BioSolutions
- Q3 sales and earnings fell; revenue and EBITDA guidance declined as margin guidance rose.EBS
Q3 2026 - Ballot: three director nominees, auditor ratification, and 2024 executive pay approval.EBSProxy Filing
- Strong 2026 results, expanded global reach, and innovation drive growth amid evolving health threats.EBSH.C. Wainwright 28th Annual Global Investment Conference
- Q2 2026 saw strong MCM growth but a $191.3M NARCAN® impairment drove a $180.2M net loss.EBSQ2 2026
- Turnaround delivers strong EBITDA, innovation, and global growth in biodefense and opioid solutions.EBSGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Turnaround delivers strong Q1 2026 results, with growth from innovation and global expansion.EBSJefferies Global Healthcare Conference 2026
- Q1 2026 revenue beat guidance but fell 30% year-over-year; liquidity and outlook remain strong.EBSQ1 2026
- Strong financial turnaround, all proposals approved, and growth-focused strategies outlined.EBSAGM 2026
- Q3 2024 net income jumped 144% and adjusted EBITDA rose 432% as guidance was raised.EBSQ3 2024